Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
McCarthy JS, Donini C, Chalon S, Woodford J, Marquart L, Collins KA, Rozenberg FD, Fidock DA, Cherkaoui-Rbati MH, Gobeau N, Möhrle JJ. McCarthy JS, et al. Among authors: cherkaoui rbati mh. Clin Infect Dis. 2020 Dec 17;71(10):e657-e664. doi: 10.1093/cid/ciaa368. Clin Infect Dis. 2020. PMID: 32239164 Free PMC article. Clinical Trial.
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria.
Adoke Y, Zoleko-Manego R, Ouoba S, Tiono AB, Kaguthi G, Bonzela JE, Duong TT, Nahum A, Bouyou-Akotet M, Ogutu B, Ouedraogo A, Macintyre F, Jessel A, Laurijssens B, Cherkaoui-Rbati MH, Cantalloube C, Marrast AC, Bejuit R, White D, Wells TNC, Wartha F, Leroy D, Kibuuka A, Mombo-Ngoma G, Ouattara D, Mugenya I, Phuc BQ, Bohissou F, Mawili-Mboumba DP, Olewe F, Soulama I, Tinto H; FALCI Study Group. Adoke Y, et al. Among authors: cherkaoui rbati mh. Malar J. 2021 May 19;20(1):222. doi: 10.1186/s12936-021-03749-4. Malar J. 2021. PMID: 34011358 Free PMC article. Clinical Trial.
A pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria.
Cherkaoui-Rbati MH, Andenmatten N, Burgert L, Egbelowo OF, Fendel R, Fornari C, Gabel M, Ward J, Möhrle JJ, Gobeau N. Cherkaoui-Rbati MH, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):50-61. doi: 10.1002/psp4.12875. Epub 2022 Nov 22. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36412499 Free PMC article.
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro.
Walz A, Duffey M, Aljayyoussi G, Sax S, Leroy D, Besson D, Burrows JN, Cherkaoui-Rbati MH, Gobeau N, Westwood MA, Siethoff C, Gamo FJ, Mäser P, Wittlin S. Walz A, et al. Among authors: cherkaoui rbati mh. Pharmaceuticals (Basel). 2023 Jan 23;16(2):163. doi: 10.3390/ph16020163. Pharmaceuticals (Basel). 2023. PMID: 37009844 Free PMC article.
New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations.
Wicha SG, Walz A, Cherkaoui-Rbati MH, Bundgaard N, Kuritz K, Gumpp C, Gobeau N, Möhrle J, Rottmann M, Demarta-Gatsi C. Wicha SG, et al. Among authors: cherkaoui rbati mh. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0055622. doi: 10.1128/aac.00556-22. Epub 2022 Oct 5. Antimicrob Agents Chemother. 2022. PMID: 36197116 Free PMC article.
Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment.
Radohery GFR, Walz A, Gumpp C, Cherkaoui-Rbati MH, Gobeau N, Gower J, Davenport MP, Rottmann M, McCarthy JS, Möhrle JJ, Rebelo M, Demarta-Gatsi C, Khoury DS. Radohery GFR, et al. Among authors: cherkaoui rbati mh. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0011422. doi: 10.1128/aac.00114-22. Epub 2022 Jun 21. Antimicrob Agents Chemother. 2022. PMID: 35727057 Free PMC article.
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance.
Murithi JM, Pascal C, Bath J, Boulenc X, Gnädig NF, Pasaje CFA, Rubiano K, Yeo T, Mok S, Klieber S, Desert P, Jiménez-Díaz MB, Marfurt J, Rouillier M, Cherkaoui-Rbati MH, Gobeau N, Wittlin S, Uhlemann AC, Price RN, Wirjanata G, Noviyanti R, Tumwebaze P, Cooper RA, Rosenthal PJ, Sanz LM, Gamo FJ, Joseph J, Singh S, Bashyam S, Augereau JM, Giraud E, Bozec T, Vermat T, Tuffal G, Guillon JM, Menegotto J, Sallé L, Louit G, Cabanis MJ, Nicolas MF, Doubovetzky M, Merino R, Bessila N, Angulo-Barturen I, Baud D, Bebrevska L, Escudié F, Niles JC, Blasco B, Campbell S, Courtemanche G, Fraisse L, Pellet A, Fidock DA, Leroy D. Murithi JM, et al. Among authors: cherkaoui rbati mh. Sci Transl Med. 2021 Jul 21;13(603):eabg6013. doi: 10.1126/scitranslmed.abg6013. Sci Transl Med. 2021. PMID: 34290058 Free PMC article.
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.
Chughlay MF, El Gaaloul M, Donini C, Campo B, Berghmans PJ, Lucardie A, Marx MW, Cherkaoui-Rbati MH, Langdon G, Angulo-Barturen I, Viera S, Rosanas-Urgell A, Van Geertruyden JP, Chalon S. Chughlay MF, et al. Among authors: cherkaoui rbati mh. Am J Trop Med Hyg. 2021 Feb 8;104(4):1348-1358. doi: 10.4269/ajtmh.20-1165. Am J Trop Med Hyg. 2021. PMID: 33556040 Free PMC article.